Butamirate
Based on 1 Customer Validation
Butamirate is an orally active antitussive agent that acts centrally through the receptors in the brainstem. Butamirate also reduces the resistance in the airways by inhibiting bronchospasm and anti-inflammatory effect. Butamirate inhibits glioblastoma (GBM) growth and STAT3 activity. Butamirate can be used for the study of glioblastoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.48%
- CAS No.: 18109-80-3
- Formule: C18H29NO3
- Masse moléculaire:307.43
-
Stockage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Cancer Stem Cells Compound Library
HY-L135
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
Butamirate (0.01-10 μM; 7 days) could effectively suppress sphere formation and STAT3 activity[2].
Butamirate effectively inhibits interactions of RRAD with pSTAT3[2].
Butamirate shows decreased EGFR, STAT3, ERK and AKT phosphorylation in U87MG[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U87MG, U87MG-TMZ-resistant (U87 TMZR), U87MG-Lapatinib-resistant (U87 LAPAR) and T98G (TMZ resistant) tumorspheres
-
Concentration:0.01-10 μM
-
Incubation Time:7 days
-
Result:Effectively suppressed growth of glioblastoma cell lines, including U87MG-TMZR and U87MG-LAPAR.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c nude mice (6- to 8 week-old) were subcutaneously injected with U87MG cells[2]
-
Dosage:2 mg/kg
-
Administration:i.p; once a day; for 36 days.
-
Result:Inhibited tumor growth in a glioblastoma mouse xenograft model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 18109-80-3
-
Appearance Liquid (Density: 1.007±0.06 g/cm3)
-
Masse moléculaire 307.43
-
Formule C18H29NO3
-
Color Yellow to orange
-
SMILES
O=C(C(C1=CC=CC=C1)CC)OCCOCCN(CC)CC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (325.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Płusa T. et al. Butamirate citrate in control of cough in respiratory tract inflammation. Pol Merkur Lekarski. 2017 Aug 21;43(254):69-74. [Content Brief]
[2]. Lee SJ, et al. Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents. Sci Rep. 2021 May 12;11(1):10145. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2528 mL | 16.2639 mL | 32.5277 mL | 81.3193 mL |
| 5 mM | 0.6506 mL | 3.2528 mL | 6.5055 mL | 16.2639 mL | |
| 10 mM | 0.3253 mL | 1.6264 mL | 3.2528 mL | 8.1319 mL | |
| 15 mM | 0.2169 mL | 1.0843 mL | 2.1685 mL | 5.4213 mL | |
| 20 mM | 0.1626 mL | 0.8132 mL | 1.6264 mL | 4.0660 mL | |
| 25 mM | 0.1301 mL | 0.6506 mL | 1.3011 mL | 3.2528 mL | |
| 30 mM | 0.1084 mL | 0.5421 mL | 1.0843 mL | 2.7106 mL | |
| 40 mM | 0.0813 mL | 0.4066 mL | 0.8132 mL | 2.0330 mL | |
| 50 mM | 0.0651 mL | 0.3253 mL | 0.6506 mL | 1.6264 mL | |
| 60 mM | 0.0542 mL | 0.2711 mL | 0.5421 mL | 1.3553 mL | |
| 80 mM | 0.0407 mL | 0.2033 mL | 0.4066 mL | 1.0165 mL | |
| 100 mM | 0.0325 mL | 0.1626 mL | 0.3253 mL | 0.8132 mL |
Butamirate Related Classifications
HY-118545 Related Classifications
Powered by Bioz